gemcitabine has been researched along with Bone Cancer in 116 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (0.86) | 18.2507 |
2000's | 48 (41.38) | 29.6817 |
2010's | 60 (51.72) | 24.3611 |
2020's | 7 (6.03) | 2.80 |
Authors | Studies |
---|---|
Blanco-Prieto, MJ; Couvreur, P; Desmaële, D; Rodríguez-Nogales, C; Sebastián, V | 1 |
Gong, H; Xu, H; Zhang, G | 1 |
Gowda, PS; Javed, A; Li, J; Lu, Y; Ponnazhagan, S; Trotter, TN; Xu, X; Yang, Y; Zhang, C | 1 |
Song, JX; Yuan, BS; Yuan, Y; Zhang, MN | 1 |
Fitzpatrick, FC; Sabile, JMG; Skelton, MR; Stump, MS | 1 |
Abdelhamid, AH; Agarwal, S; Bobbili, PJ; Chugh, R; Demetri, GD; Duh, MS; Gounder, MM; Huynh, L; Lax, AK; Merriam, P; Patel, SR; Rajarethinam, A; Ratan, R; Thornton, M; Totev, TI; Van Tine, BA; Villalobos, VM; Whalen, J; Yang, J | 1 |
Huang, Z; Lin, J; Shen, R; Wang, S; Wang, X; Wei, H; Wu, Z | 1 |
Ahn, JS; Awada, A; Cortés, J; Diéras, V; Gómez-Pardo, P; Hannah, AL; Hoch, U; Im, SA; Mailliez, A; Moreno-Aspitia, A; O'Shaughnessy, J; Perez, EA; Potter, DA; Rugo, HS; Schwartzberg, LS; Tagliaferri, M; Twelves, C; Yardley, DA; Zhao, C | 1 |
Chiba, N; Imai, H; Ishioka, C; Komine, K; Mori, T; Ohori, H; Okada, Y; Saijo, K; Shimodaira, H; Shirota, H; Takahashi, M; Takahashi, S | 1 |
Chen, F; Hu, Y; Li, H; Liu, H; Tao, H; Wang, Y | 1 |
Castañeda, A; Cruz, J; Cruz, O; de Alava, E; de Torres, C; Garcia Del Muro, X; Lopez-Pousa, A; Maradiegue, E; Martin-Broto, J; Martinez-Trufero, J; Maurel, J; Mora, J; Perez-Jaume, S; Valverde, C; Vaz, MA | 1 |
Carnero, A; Carranza, A; Cruz, J; Diaz-Beveridge, R; Encinas, V; Garcia Del Muro, X; Gutierrez, A; Hindi, N; Lopez-Pousa, A; Luna, P; Marcilla, D; Martin-Broto, J; Martinez-Trufero, J; Mora, J; Moura, DS; Redondo, A; Sancho, P; Taron, M; Tous, C; Valverde, C; Vaz, MA | 1 |
Li, D; Liu, J; Lu, Y; Wang, S; Wang, Y | 1 |
Caliskan, Y; Dalgic, AD; Gerekci, S; Gulec, EA; Keskin, D; Ozen, C; Tezcaner, A | 1 |
Jian, YK; Li, B; Sun, ZY; Zhu, HY | 1 |
Chang, YJ; Chen, HA; Huang, CY; Huang, MT; Makondi, PT; Wang, JW; Wei, PL | 1 |
Cheng, R; Cui, W; Dai, Y; Liu, H; Ni, Q; Wu, W; Ye, T | 1 |
El-Hadaad, HA; Wahba, HA | 1 |
Singer, A; Tresley, J; Velazquez-Vega, J; Yepes, M | 1 |
Hiramatsu, Y; Shibahara, H | 1 |
Chen, MY; Guo, L; Hong, MH; Huang, HQ; Jiang, R; Liu, Q; Mai, HQ; Qian, CN; Qiu, F; Sun, R; Xia, ZJ; Zhang, L; Zou, X | 1 |
Fukawa, T; Fukumori, T; Izaki, H; Kagawa, J; Kanayama, HO; Komori, M; Oi, H; Oyama, T; Sasaki, Y; Senzaki, T; Takahashi, H; Takahashi, M; Takemura, M; Yamaguchi, K; Yamamoto, Y | 1 |
Altiok, S; Foroutan, P; Gillies, RJ; Grove, O; Kreahling, JM; Lloyd, MC; Martinez, GV; Morse, DL; Raghavan, M; Reed, D | 1 |
Jinno, H; Kitagawa, Y; Kitasato, K; Murai, S; Nakadai, J; Oto, I; Shimizu, H; Yabe, N; Yoshikawa, T | 1 |
Cao, J; Huang, XE; Liu, J; Lu, YY; Wu, XY | 1 |
Chi, Y; Song, Y; Wang, J; Yang, L; Zhou, A | 1 |
Gordon, N; O'Farrill, JS | 1 |
Huang, G; Kleinerman, ES; Nishimoto, K; Yang, Y | 1 |
Rodriguez, CO | 1 |
Carbone, A; Di Cristofano, C; Evangelista, S; Palleschi, G; Pastore, AL; Petrozza, V; Porta, N; Rossi, L; Silvestri, L; Tomao, S | 1 |
Wang, WM; Wei, MY; Zhuang, YF | 1 |
Wang, W; Wang, Z; Xiao, X | 1 |
Faez, L; Garrido, M; Jiménez-Fonseca, P; Menendez, MD; Rodriguez, D; Ruiz, AL; Sanchez Lorenzo, ML; Solis, MP; Uriol, E; Viéitez, JM | 1 |
Chen, YY; Chiang, PH; Hsieh, MC; Huang, CH; Rau, KM; Su, YL | 1 |
Agerbaek, M; Cerbone, L; Collette, S; Daugaard, G; Marreaud, S; Sengeløv, L; Sternberg, CN; Van Herpen, C; Zhang, J | 1 |
Cousin, S; Ducoulombier, A; Kotecki, N; Penel, N | 1 |
Kim, DH; Kim, MS; Lee, JA; Lim, JS; Paik, EK; Seo, J; Yoo, JY | 1 |
Gan, ZH; Han, K; Hu, HY; Li, KP; Lin, SC; Liu, Y; Lu, ZG; Min, DL; Tseng, KF; Zhao, RH; Zhou, Y | 1 |
Ahn, HS; Baek, HJ; Cho, WH; Choi, HS; Im, HJ; Jeon, DG; Kang, HJ; Koh, KN; Koo, HH; Kook, H; Lee, JA; Lee, JW; Lim, YJ; Park, BK; Park, HJ; Park, KD; Seo, JJ; Shin, HY; Song, WS; Sung, KW; Yoo, KH; Yoon, HS | 1 |
Kitawaki, J; Kokabu, T; Konishi, E; Mori, T; Tsukasaki, N; Yasukawa, S | 1 |
Blackwood, E; Cao, Y; Evangelista, M; Klijn, C; Lee, HJ; Pham, V; Settleman, J; Stokoe, D; Wilson, C | 1 |
Hee, SW; Leong, SS; Lim, WT; Poon, D; Rajan, S; Tan, EH; Tay, MH; Toh, CK; Wee, J | 1 |
Hokkoku, K; Kiba, T; Mizuno, T; Mori, M; Nakagawa, T; Nakai, M; Oikawa, M; Sakuma, H; Shintaku, K; Ueda, H; Watanabe, Y; Yoshimitsu, Y | 1 |
Bae, SB; Cheon, YG; Cho, YD; Hong, DS; Kim, CK; Kim, HJ; Kim, YS; Lee, KT; Lee, NS; Lee, SC; Moon, JH; Park, HS; Park, SH; Park, SK; Won, JH | 1 |
Hisada, T; Imai, H; Ishizuka, T; Kaira, K; Kawata, T; Mori, M; Shimizu, K; Sunaga, N; Utsugi, M; Yanagitani, N | 1 |
Hartmann, JT; Horger, M; Kanz, L; Mayer, F; Meisinger, I; Pintoffl, J; von Weyhern, C | 1 |
Chang, PY; Chen, JH; Yao, NS | 1 |
Gorlick, R; O'Day, K | 1 |
Ding, L; Duan, LN; Liu, J; Wang, HX; Wang, ZD; Xue, M; Yan, HM; Zhu, L | 1 |
Esser, N; Graeser, R; Jantscheff, P; Kluth, J; Massing, U; Sukolinskaya, A; Taylor, LA; Unger, C; Ziroli, V | 1 |
Anderson, PM; Cannan, VA; Crabbs, TA; Gordon, N; Kleinerman, E; Koshkina, N; Rodriguez, CO; Skorupski, KA; Wilson, DW | 1 |
Feng, J; Liu, B; Shi, ZL; Tao, HM; Yan, XB; Zhang, B | 1 |
Gupta, S; Mallik, S; Munshi, A | 1 |
Alamara, C; Charpidou, A; Kotanidou, A; Makrilia, N; Nikolaidis, I; Ralli, M; Syrigos, K; Tourkantonis, I; Tsimpoukis, S | 1 |
Daugaard, G; Gothelf, A; Møller, AK; Pedersen, KD | 1 |
Gordon, N; Kleinerman, ES | 1 |
Bear, MD; Kulp, SK; London, CA; McMahon, MB; Pennell, ML | 1 |
Heike, Y; Ikeda, M; Kaida, M; Kojima, Y; Kondo, S; Morita-Hoshi, Y; Morizane, C; Okusaka, T; Soeda, A; Ueno, H; Wakeda, T; Yamaki, Y | 1 |
Jeske, S; Kung, S; Lehrer, D; Matulich, D; Mazumdar, M; Milowsky, MI; Nanus, DM; Selzer, J; Sung, M; Tagawa, ST; Wright, JJ | 1 |
Goto, H; Ko, SB | 1 |
Bergerat, JP; Delpeuch, A; Leveque, D; Rob, L | 1 |
Abele, JT; El-Mabhouh, AA; McEwan, AJ; Mercer, JR; Nation, PN; Postema, E; Riauka, T | 1 |
Ahn, JH; Lee, EM; Lee, J; Park, KH; Rha, SY | 1 |
Ben-Ami, T; Gosiengfiao, Y; Reichek, J; Walterhouse, D; Woodman, J | 1 |
Lai, J; Li, H; Liang, C; Liu, B; Shen, C; Shi, Z; Tao, HM | 1 |
Benjamin, RS; Chawla, S; Chugh, R; Fox, E; Harmon, D; Helman, LJ; Patel, S; Reinke, D; Schuetze, S; Wathen, JK | 1 |
He, AN; Lin, F; Qi, WX; Shen, Z; Tang, LN; Yao, Y | 1 |
Alici, S; Alkiş, N; Benekli, M; Berk, V; Büyükberber, S; Camci, C; Coskun, U; Esbah, O; Kaya, AO; Ozdemir, NY; Ozkan, M; Sevinc, A; Ulas, A | 1 |
He, A; Huang, Y; Qi, W; Shen, Z; Sun, Y; Yang, Y; Yao, Y; Zhao, H | 1 |
Araujo, JC; Jonasch, E; Lim, ZD; Lin, E; Ng, CS; Pagliaro, LC; Richey, SL; Sharma, P; Tamboli, P; Tannir, NM | 1 |
Bertetto, O; Ceccarelli, M; Chiappino, I; Ciccone, G; Ciuffreda, L; Giacobino, A; Napoletano, R; Novarino, AM; Satolli, MA; Schena, M | 1 |
Arslan, M; Ceylan, Y; Degirmenci, T; Gunlusoy, B; Kara, C; Kozacıoğlu, Z; Vardar, E | 1 |
Hwang, EC; Hwang, IS; Hwang, JE; Jung, SI; Kang, TW; Kim, SO; Kwon, DD; Park, K; Ryu, SB; Yu, HS | 1 |
Chen, LK; Liang, Y; Liu, GZ; Wei, WD; Xu, F; Xu, GC; Yang, QY; Zhou, NN | 1 |
Hassali, MA; Hassan, BA; Othman, SB; Weiderpass, E; Yusoff, ZB | 1 |
Lim, YL; Tay, EY | 1 |
Colle, B; Debourdeau, P; Estival, JL; Pavic, M; Teixeira, L; Zammit, C | 1 |
Calabrese, P; Caporusso, L; Catino, A; Crucitta, E; D'Amico, C; De Lena, M; Guida, M; Latorre, A; Lorusso, V; Mazzei, A; Sambiasi, D; Schittulli, F; Silvestris, N | 1 |
Arai, Y; Endo, M; Hagisawa, S; Hiramatu, M; Hoshi, S; Ohyama, C; Satoh, M; Watanabe, R | 1 |
Delpassand, ES; Logothetis, CJ; Millikan, RE; Pagliaro, LC; Tu, SM; Williams, D | 1 |
Lambiase, L; Li, J; Monteiro, C; Robinson, K; Schiff, M | 1 |
Bickels, J; Inbar, M; Kollender, Y; Meller, I; Merimsky, O | 1 |
Depisch, D; Gruenberger, T; Karall, K; Kornek, GV; Laengle, F; Lang, F; Penz, M; Scheithauer, W; Schuell, B | 1 |
Aravantinos, G; Farmakis, D; Gaglia, A; Kostopoulou, V; Koumpou, M; Mylonakis, N; Nikolaou, M; Pectasides, D; Pectasides, M; Skarlos, D | 1 |
Baker, LH; Biermann, JS; Couwlier, C; Lee, JS; Leu, KM; Ostruszka, LJ; Palazzolo, K; Shewach, D; Sondak, V; Zalupski, M | 1 |
Bessis, D; Guilhou, JJ; Guillot, B; Legouffe, E | 1 |
deVere White, RW; Ellison, LM; Gandour-Edwards, R; Goldberg, Z; Karpman, E; Saffarian, A | 1 |
Han, H; Liu, ZW; Qin, ZK; Wu, ZG; Yang, GW; Zhou, FJ; Zhou, NN | 1 |
Komut, K; Minami, S | 1 |
Kleinerman, ES; Koshkina, NV | 1 |
Bach, AM; Choi, J; Currie, VE; D'Andrea, GM; Hudis, CA; Lake, DE; Moasser, MM; Modi, S; Norton, L; Panageas, KS; Seidman, AD; Theodoulou, M | 1 |
Ando, T; Hamada, Y; Ichikawa, J; Nakao, A; Okamoto, A; Tasaka, K | 1 |
Brodsky, I; Rosenbluth, JZ; Styler, MJ; Zak, D | 1 |
Albritton, K; Anderson, PM; Dubansky, SA; Erlandson, L; Rodriguez, V; Trotz, B; Wiseman, GA | 1 |
Chang, YS; Cho, JY; Chung, JB; Lee, DK; Lee, SJ; Paik, YH; Park, MS; Song, SY; Yoon, DS; Yu, JS | 1 |
Funakoshi, A; Iguchi, H; Sumii, T | 1 |
Budman, DR; Calabro, A | 1 |
Ito, Y; Tokudome, N | 1 |
Angelov, CA; Cavell, R; El-Mabhouh, AA; Mercer, JR | 1 |
Fujioka, H; Hatano, K; Honda, M; Matsumiya, K; Satoh, M; Takada, T; Tsujimoto, Y | 1 |
Hibi, T; Higuchi, H; Hisamatsu, T; Iizuka, H; Iwasaki, E; Izumiya, M; Masaoka, T; Nagata, H; Nishizawa, T; Suzuki, H; Takaishi, H; Yamagishi, Y | 1 |
Arcara, C; Badalamenti, G; Caraceni, A; Cicero, G; Fulfaro, F; Gebbia, N; Intrivici, C | 1 |
Akerley, W; Atkins, JN; Bearden, JD; Chansky, K; Crowley, JJ; Gandara, DR; Goodwin, JW; Hesketh, PJ; McCoy, J | 1 |
Gordon, N; Jia, SF; Khanna, C; Kleinerman, ES; Koshkina, NV; Mendoza, A; Worth, LL | 1 |
El-Mabhouh, AA; Mercer, JR | 1 |
Hirobe, M; Itoh, T; Kunishima, Y; Masumori, N; Takayanagi, A; Takeuchi, M; Tsukamoto, T | 1 |
Epstein, RJ; Leung, TW | 1 |
Boeck, S; Bruns, CJ; Golf, A; Haas, M; Heinemann, V; Issels, RD; Laessig, D; Moosmann, N; Schulz, C; Wilkowski, R | 1 |
Kennedy, MJ | 1 |
Ariad, S; Fenig, E; Flusser, G; Inbar, M; Issakov, J; Kollender, Y; Meller, I; Merimsky, O; Neuman, G; Sapir, D; Weil-Ben-Arush, M | 1 |
Bauer, J; Bernhard, J; Borner, M; Fey, MF; Hanselmann, S; Hering, F; Hürny, C; Jacky, E; Maibach, R; Morant, R; Thürlimann, B; Trinkler, F; Zulian, G | 1 |
Geissler, M; Ness, T; Schmidt, D | 1 |
Ambinder, R; Blackstein, M; Cowan, J; Iglesias, J; Melemed, A; Vogel, CL | 1 |
Brugnatelli, S; Danova, M; De Bella, MT; Manuguerra, G; Palmeri, S; Riccardi, A; Vaglica, M | 1 |
Salman, HS; Sparano, JA; Tanaka, K | 1 |
Hisada, T; Ito, T; Masuda, S; Mochida, A; Morinari, H; Nakahara, K; Nishi, K; Saito, K; Sasaki, S; Tahara, M; Yakumaru, K | 1 |
17 review(s) available for gemcitabine and Bone Cancer
Article | Year |
---|---|
Unusual aggressive breast cancer: metastatic malignant phyllodes tumor.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Deoxycytidine; Female; Fibroadenoma; Gemcitabine; Humans; Ifosfamide; Muscle Neoplasms; Naphthacenes; Neoplasm Invasiveness; Palliative Care; Phyllodes Tumor; Prognosis | 2013 |
Autophagy in osteosarcoma.
Topics: Animals; Antimetabolites, Antineoplastic; Autophagy; Bone and Bones; Bone Neoplasms; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Hydroxychloroquine; Lung; Lung Neoplasms; Mice; Osteosarcoma; Species Specificity | 2014 |
Participation of the Fas/FasL signaling pathway and the lung microenvironment in the development of osteosarcoma lung metastases.
Topics: Animals; Antineoplastic Agents; Benzamides; Bone Neoplasms; Deoxycytidine; Epigenesis, Genetic; Fas Ligand Protein; fas Receptor; Gemcitabine; Humans; Lung Neoplasms; Mice; MicroRNAs; Osteosarcoma; Pyridines; RNA, Long Noncoding; Signal Transduction; Tumor Microenvironment | 2014 |
Using canine osteosarcoma as a model to assess efficacy of novel therapies: can old dogs teach us new tricks?
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Aerosols; Animals; Antineoplastic Agents; Bone Neoplasms; Child; Deoxycytidine; Dog Diseases; Dogs; Gemcitabine; Humans; Interleukin-2; Lung Neoplasms; Molybdenum; Osteosarcoma; Phosphatidylethanolamines; Signal Transduction | 2014 |
Gemcitabine for the treatment of patients with osteosarcoma.
Topics: Antimetabolites, Antineoplastic; Bone Neoplasms; Deoxycytidine; Gemcitabine; Humans; Osteosarcoma; Treatment Outcome | 2014 |
The role of chemotherapy for metastatic, relapsed and refractory osteosarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; Deoxycytidine; Docetaxel; Etoposide; Gemcitabine; Humans; Ifosfamide; Methotrexate; Neoplasm Recurrence, Local; Osteosarcoma; Taxoids | 2014 |
Gemcitabine-based chemotherapy in sarcomas: A systematic review of published trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Deoxycytidine; Gemcitabine; Humans; Leiomyosarcoma; Osteosarcoma; Sarcoma | 2016 |
Novel therapeutic agents for osteosarcoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; Child; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Diphosphonates; Docetaxel; Dogs; Drug Delivery Systems; Folic Acid Antagonists; Gemcitabine; Humans; Immunologic Factors; Neoadjuvant Therapy; Neoplasm Proteins; Osteosarcoma; Protein Kinase Inhibitors; Radiopharmaceuticals; Signal Transduction; Survival Rate; Taxoids; Xenograft Model Antitumor Assays; Young Adult | 2009 |
Aerosol therapy for the treatment of osteosarcoma lung metastases: targeting the Fas/FasL pathway and rationale for the use of gemcitabine.
Topics: Aerosols; Animals; Antimetabolites, Antineoplastic; Bone Neoplasms; Deoxycytidine; Fas Ligand Protein; fas Receptor; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Osteosarcoma | 2010 |
[Gemcitabine-induced thrombotic microangiopathy].
Topics: Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; Deoxycytidine; Gemcitabine; Humans; Male; Neoplasm Metastasis; Thrombosis; Urologic Neoplasms; Vascular Diseases | 2002 |
Active chemotherapy for bone metastasis in sarcomatoid renal cell carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bone Neoplasms; Carboplatin; Carcinoma, Renal Cell; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gemcitabine; Humans; Immunohistochemistry; Kidney Neoplasms; Neoplasm Staging; Nephrectomy; Paclitaxel; Sarcoma; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2003 |
Palliative treatment for advanced or metastatic osteosarcoma.
Topics: Amputation, Surgical; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Cisplatin; Combined Modality Therapy; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Neoplasm Recurrence, Local; Osteosarcoma; Palliative Care; Pneumonectomy; Prognosis; Radiotherapy, Adjuvant; Severity of Illness Index; Survival Rate; Treatment Outcome | 2004 |
Analysis of treatment for small cell cancer of the bladder and report of three cases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Biomarkers, Tumor; Bone Neoplasms; Carboplatin; Carcinoma, Small Cell; Carcinoma, Transitional Cell; Cisplatin; Combined Modality Therapy; Cystectomy; Deoxycytidine; Disease Progression; Etoposide; Gemcitabine; Humans; Life Tables; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasms, Second Primary; Prostatectomy; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms; Urinary Diversion | 2004 |
Combination of gemcitabine and irinotecan for recurrent metastatic osteogenic sarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Cisplatin; Combined Modality Therapy; Deoxycytidine; Doxorubicin; Etoposide; Femoral Neoplasms; Gemcitabine; Head and Neck Neoplasms; Humans; Ifosfamide; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Methotrexate; Middle Aged; Neoadjuvant Therapy; Osteosarcoma; Palliative Care; Salvage Therapy; Scalp; Skin Neoplasms; Thoracotomy | 2005 |
[Multimodal therapy for advanced pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Bone Neoplasms; Combined Modality Therapy; Deoxycytidine; Drug Therapy; Gemcitabine; Humans; Liver Neoplasms; Palliative Care; Pancreatic Neoplasms; Peripheral Blood Stem Cell Transplantation; Radiation-Sensitizing Agents; Radiotherapy; Radiotherapy Dosage | 2006 |
[Chemotherapy for metastatic breast cancer].
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Diphosphonates; Doxorubicin; Female; Fluorouracil; Gemcitabine; Humans; Meta-Analysis as Topic; Quality of Life; Receptor, ErbB-2; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2006 |
Metastatic breast cancer.
Topics: Adenine; Antibodies, Monoclonal; Antibodies, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Diphosphonates; Docetaxel; Doxorubicin; Enzyme Inhibitors; Female; Gemcitabine; Humans; Imides; Intercalating Agents; Isoquinolines; Naphthalimides; Neoplasm Metastasis; Neoplasm Proteins; Organophosphonates; Paclitaxel; Randomized Controlled Trials as Topic; Salvage Therapy; Taxoids; Topoisomerase II Inhibitors; Treatment Outcome | 1996 |
28 trial(s) available for gemcitabine and Bone Cancer
Article | Year |
---|---|
Analysis of the Mechanism and Safety of Bisphosphonates in Patients with Lung Cancer and Bone Metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Cisplatin; Computational Biology; Deoxycytidine; Diphosphonates; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Safety; Young Adult; Zoledronic Acid | 2021 |
Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Albumins; Anorexia; Antineoplastic Agents; Body Image; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Cancer Pain; Deoxycytidine; Docetaxel; Dyspnea; Epothilones; Fatigue; Female; Furans; Gemcitabine; Health Status; Heterocyclic Compounds, 4 or More Rings; Humans; Ketones; Liver Neoplasms; Lung Neoplasms; Middle Aged; Nausea; Paclitaxel; Polyethylene Glycols; Quality of Life; Reproductive Health; Sleep Initiation and Maintenance Disorders; Taxoids; Vinblastine; Vinorelbine; Vomiting | 2017 |
GEIS-21: a multicentric phase II study of intensive chemotherapy including gemcitabine and docetaxel for the treatment of Ewing sarcoma of children and adults: a report from the Spanish sarcoma group (GEIS).
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; Deoxycytidine; Disease-Free Survival; Docetaxel; Gemcitabine; Humans; Kaplan-Meier Estimate; Odds Ratio; Prognosis; Prospective Studies; Sarcoma, Ewing; Spain; Survival Rate; Taxoids | 2017 |
Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS).
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Osteosarcoma; Recurrence; Sirolimus; Young Adult | 2017 |
Oxaliplatin plus 5-fluorouracil and folinic acid (OFF) in gemcitabine-pretreated advanced pancreatic cancer: a phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Survival Rate | 2013 |
Results from a Phase I Study of Lapatinib with Gemcitabine and Cisplatin in Advanced or Metastatic Bladder Cancer: EORTC Trial 30061.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Febrile Neutropenia; Female; Gemcitabine; Humans; International Cooperation; Lapatinib; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Quinazolines; Receptor, ErbB-2; Renal Insufficiency; Treatment Outcome; Urinary Bladder Neoplasms | 2016 |
A phase II study of gemcitabine in combination with oxaliplatin as first-line chemotherapy in patients with inoperable biliary tract cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Bone Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Prognosis; Prospective Studies; Survival Rate; Treatment Outcome | 2009 |
Phase II study of gemcitabine plus docetaxel as second-line treatment in malignant pleural mesothelioma: a single institution study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Deoxycytidine; Disease Progression; Docetaxel; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Male; Mesothelioma; Middle Aged; Neoplasm Staging; Pleural Neoplasms; Salvage Therapy; Survival Rate; Taxoids; Treatment Outcome | 2011 |
Paclitaxel, cisplatin and gemcitabine in treatment of carcinomas of unknown primary site, a phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Neoplasms; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Risk Factors; Treatment Outcome | 2010 |
A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bone Neoplasms; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Rate; Treatment Outcome | 2011 |
Phase II study of weekly docetaxel and fixed dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Deoxycytidine; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Gemcitabine; Humans; Injections, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Prospective Studies; Sarcoma; Taxoids; Young Adult | 2012 |
Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003.
Topics: Adolescent; Adult; Aged; Bone Neoplasms; Chondrosarcoma; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Osteosarcoma; Sarcoma, Ewing; Taxoids | 2012 |
Phase II trial of pemetrexed plus gemcitabine in patients with locally advanced and metastatic nonclear cell renal cell carcinoma.
Topics: Adolescent; Adrenal Gland Neoplasms; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Renal Cell; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Infusions, Intravenous; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Pemetrexed; Prognosis; Survival Rate; Young Adult | 2013 |
FOLFOX-4 regimen or single-agent gemcitabine as first-line chemotherapy in advanced biliary tract cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Bone Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Young Adult | 2013 |
[The efficacy and toxicity of gemcitabine and cisplatin chemotherapy in advanced/metastatic bladder urothelial carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cisplatin; Combined Modality Therapy; Cystectomy; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neutropenia; Salvage Therapy; Thrombocytopenia; Treatment Outcome; Urinary Bladder Neoplasms | 2012 |
Phase I/II study of gemcitabine plus mitoxantrone as salvage chemotherapy in metastatic breast cancer.
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Gemcitabine; Heart Diseases; Humans; Lymphatic Metastasis; Male; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Salvage Therapy; Soft Tissue Neoplasms | 2003 |
A Phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastases.
Topics: Aged; Bone Neoplasms; Carcinoma; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Injections, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Radiation-Sensitizing Agents; Strontium; Strontium Radioisotopes; Testosterone | 2003 |
Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Bone Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mitomycin; Neoplasm Staging; Treatment Outcome | 2004 |
Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: a phase II study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Cisplatin; Deoxycytidine; Female; Gemcitabine; Germinoma; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Mediastinal Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Gonadal Tissue; Organoplatinum Compounds; Oxaliplatin; Remission Induction; Salvage Therapy; Treatment Outcome | 2004 |
A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Bridged-Ring Compounds; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Liver Neoplasms; Lung Neoplasms; Middle Aged; Nausea; Neoadjuvant Therapy; Neoplasm Staging; Prognosis; Salvage Therapy; Skin Neoplasms; Soft Tissue Neoplasms; Survival Analysis; Taxoids; Treatment Outcome; Vomiting | 2005 |
Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Biopsy, Needle; Bone Neoplasms; Capecitabine; Carcinoma, Ductal; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Immunohistochemistry; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Risk Assessment; Survival Analysis; Treatment Outcome | 2005 |
Gemcitabine and irinotecan for patients with untreated extensive stage small cell lung cancer: SWOG 0119.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Carcinoma, Small Cell; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Prospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome | 2007 |
Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; CA-19-9 Antigen; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Salvage Therapy; Survival Rate | 2007 |
Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Bone Neoplasms; Chondrosarcoma; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Leiomyosarcoma; Male; Middle Aged; Neoplasm Recurrence, Local; Osteosarcoma; Sarcoma; Soft Tissue Neoplasms; Treatment Outcome | 2000 |
Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma. Swiss Group for Clinical Cancer Research (SAKK).
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Confidence Intervals; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Follow-Up Studies; Gemcitabine; Hormones; Humans; Infusions, Intravenous; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Pain Measurement; Palliative Care; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate | 2000 |
Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Pain Measurement; Receptors, Estrogen; Survival Analysis; Time Factors; Treatment Outcome | 2002 |
Weekly administration of gemcitabine plus docetaxel in patients with advanced breast cancer: a phase 1 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome; World Health Organization | 2002 |
Phase I/II trial of gemcitabine plus cyclophosphamide in patients with metastatic breast carcinoma previously treated with taxanes.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Bilirubin; Bone Neoplasms; Breast Neoplasms; Bridged-Ring Compounds; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Infusions, Intravenous; Liver Neoplasms; Lung Neoplasms; Middle Aged; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
71 other study(ies) available for gemcitabine and Bone Cancer
Article | Year |
---|---|
Decoration of Squalenoyl-Gemcitabine Nanoparticles with Squalenyl-Hydroxybisphosphonate for the Treatment of Bone Tumors.
Topics: Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Molecular Structure; Nanoparticles; Organophosphonates; Osteosarcoma; Squalene; Structure-Activity Relationship | 2021 |
Runx2 Deficiency in Osteoblasts Promotes Myeloma Progression by Altering the Bone Microenvironment at New Bone Sites.
Topics: Animals; Bone and Bones; Bone Marrow; Bone Neoplasms; Cell Line, Tumor; Core Binding Factor Alpha 1 Subunit; Deoxycytidine; Disease Models, Animal; Female; Fluorouracil; Gemcitabine; Humans; Male; Mice; Mice, Knockout; Multiple Myeloma; Myeloid-Derived Suppressor Cells; Osteoblasts; Tumor Microenvironment | 2020 |
A multiple drug loaded, functionalized pH-sensitive nanocarrier as therapeutic and epigenetic modulator for osteosarcoma.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Deoxycytidine; Drug Combinations; Epigenesis, Genetic; Epirubicin; Gemcitabine; Hydrogen-Ion Concentration; Male; Nanocapsules; Osteosarcoma; Particle Size; Rats; Rats, Sprague-Dawley | 2020 |
Primary Bone Marrow Epithelioid Hemangioendothelioma Treated With Gemcitabine and Docetaxel.
Topics: Bone Marrow; Bone Neoplasms; Deoxycytidine; Docetaxel; Gemcitabine; Hemangioendothelioma, Epithelioid; Humans | 2021 |
Real-world outcomes of patients with locally advanced or metastatic epithelioid sarcoma.
Topics: Adolescent; Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Deoxycytidine; Female; Gemcitabine; Health Records, Personal; Humans; Indazoles; Kaplan-Meier Estimate; Male; Middle Aged; Progression-Free Survival; Pyrimidines; Retrospective Studies; Sarcoma; Sulfonamides; Treatment Outcome; United States; Young Adult | 2021 |
Epidermal growth factor receptor promotes tumor progression and contributes to gemcitabine resistance in osteosarcoma.
Topics: Bone Neoplasms; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Gemcitabine; Humans; Neoplasm Proteins; Osteosarcoma | 2021 |
Efficacy and safety of gemcitabine plus docetaxel in Japanese patients with unresectable or recurrent bone and soft tissue sarcoma: Results from a single-institutional analysis.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bone Neoplasms; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Therapy, Combination; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Survival Rate; Taxoids; Treatment Outcome; Young Adult | 2017 |
Wnt/β-catenin signaling pathway activation reverses gemcitabine resistance by attenuating Beclin1-mediated autophagy in the MG63 human osteosarcoma cell line.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Autophagy-Related Proteins; Beclin-1; Bone Neoplasms; Caspase 3; Caspase 7; Cell Line, Tumor; Cyclin D1; Deoxycytidine; Gemcitabine; Genes, bcl-2; Humans; Lysosomal Membrane Proteins; Osteosarcoma; Wnt Signaling Pathway | 2017 |
Licoricidin enhances gemcitabine-induced cytotoxicity in osteosarcoma cells by suppressing the Akt and NF-κB signal pathways.
Topics: Animals; Antimetabolites, Antineoplastic; Benzopyrans; Bone Neoplasms; Caspase 3; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Osteosarcoma; Proto-Oncogene Proteins c-akt; Signal Transduction; Transplantation, Heterologous | 2018 |
A new therapeutic combination for osteosarcoma: Gemcitabine and Clofazimine co-loaded liposomal formulation.
Topics: Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Cell Survival; Clofazimine; Deoxycytidine; Drug Combinations; Drug Synergism; Gemcitabine; Humans; Liposomes; Osteosarcoma | 2019 |
lncRNAPVT1 targets miR-152 to enhance chemoresistance of osteosarcoma to gemcitabine through activating c-MET/PI3K/AKT pathway.
Topics: Animals; Antimetabolites, Antineoplastic; Bone Neoplasms; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Osteosarcoma; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; RNA, Long Noncoding; Signal Transduction | 2019 |
Glucose-Regulated Protein 94 Modulates the Response of Osteosarcoma to Chemotherapy.
Topics: Antineoplastic Agents; Apoptosis; Bone Neoplasms; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Epirubicin; Gemcitabine; Humans; Membrane Glycoproteins; Osteosarcoma; Paclitaxel | 2019 |
Local release of gemcitabine via in situ UV-crosslinked lipid-strengthened hydrogel for inhibiting osteosarcoma.
Topics: Animals; Antimetabolites, Antineoplastic; Bone Neoplasms; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Drug Implants; Gelatin; Gemcitabine; Humans; Hydrogels; In Vitro Techniques; Liposomes; Mice; Osteosarcoma; Ultraviolet Rays; Xenograft Model Antitumor Assays | 2018 |
[Acute pain at tumor recurrence site induced by vinorelbine infusion].
Topics: Acute Disease; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Male; Oxycodone; Pain; Vinblastine; Vinorelbine | 2013 |
Locoregional radiotherapy in patients with distant metastases of nasopharyngeal carcinoma at diagnosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Staging; Paclitaxel; Palliative Care; Radiotherapy, Intensity-Modulated; Retrospective Studies; Survival Rate; Young Adult | 2013 |
[Non-muscle invasive bladder cancer with multiple bone metastasis without local invasion : a case report].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Male; Urinary Bladder Neoplasms | 2013 |
Diffusion MRI and novel texture analysis in osteosarcoma xenotransplants predicts response to anti-checkpoint therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cell Cycle Checkpoints; Deoxycytidine; Diffusion Magnetic Resonance Imaging; Female; Gemcitabine; Humans; Mice; Mice, SCID; Middle Aged; Molecular Targeted Therapy; Osteosarcoma; Prognosis; Pyrazoles; Pyrimidines; Pyrimidinones; Treatment Outcome; Xenograft Model Antitumor Assays | 2013 |
[A case of effective trastuzumab plus gemcitabine therapy for human epidermal growth factor receptor 2-positive breast cancer].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Receptor, ErbB-2; Trastuzumab | 2013 |
Comparison of efficacy and toxicity of first line chemotherapy with or without epirubicin for patients with advanced stage soft tissue sarcoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; Deoxycytidine; Doxorubicin; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Ifosfamide; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Retrospective Studies; Sarcoma; Survival Rate; Young Adult | 2013 |
[Treatment and prognosis of 117 patients with advanced urothelial carcinoma of the bladder].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Leukopenia; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Retrospective Studies; Survival Rate; Thrombocytopenia; Urinary Bladder Neoplasms; Urothelium | 2014 |
Bone metastases from bladder perivascular epithelioid cell tumor - an unusual localization of a rare tumor: a case report.
Topics: Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; Deoxycytidine; Gemcitabine; Humans; Ilium; Male; Perivascular Epithelioid Cell Neoplasms; Tomography, X-Ray Computed; Urinary Bladder Neoplasms | 2014 |
Gemcitabine plus capecitabine (Gem-Cape) biweekly in chemorefractory metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Capecitabine; Colonic Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Peritoneal Neoplasms; Rectal Neoplasms; Retreatment; Retrospective Studies; Survival Rate | 2015 |
The comparison of oncologic outcomes between metastatic upper tract urothelial carcinoma and urothelial carcinoma of the bladder after cisplatin-based chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Deoxycytidine; Doxorubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Methotrexate; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate; Urologic Neoplasms; Vinblastine | 2015 |
Radiotherapy and gemcitabine-docetaxel chemotherapy in children and adolescents with unresectable recurrent or refractory osteosarcoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Osteosarcoma; Radiotherapy Dosage; Radiotherapy, Adjuvant; Republic of Korea; Retrospective Studies; Taxoids; Treatment Outcome | 2016 |
Sirolimus induces apoptosis and reverses multidrug resistance in human osteosarcoma cells in vitro via increasing microRNA-34b expression.
Topics: Antineoplastic Agents; Apoptosis; Bone Neoplasms; Deoxycytidine; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; HEK293 Cells; Humans; Methotrexate; MicroRNAs; Osteosarcoma; Sirolimus | 2016 |
Higher Gemcitabine Dose Was Associated With Better Outcome of Osteosarcoma Patients Receiving Gemcitabine-Docetaxel Chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Osteosarcoma; Retrospective Studies; Taxoids | 2016 |
Primary osteosarcoma of the uterine corpus: A case report.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Hysterectomy; Lung Neoplasms; Middle Aged; Osteosarcoma; Taxoids; Treatment Outcome; Uterine Neoplasms | 2016 |
Ras-MEK Signaling Mediates a Critical Chk1-Dependent DNA Damage Response in Cancer Cells.
Topics: Animals; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Checkpoint Kinase 1; Deoxycytidine; DNA Damage; Female; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 3-Ring; Humans; MAP Kinase Signaling System; Mice; Osteosarcoma; Ovarian Neoplasms; Piperidines; Proto-Oncogene Proteins p21(ras); Xenograft Model Antitumor Assays | 2017 |
Triplet combination of gemcitabine, paclitaxel, and carboplatin followed by maintenance 5-fluorouracil and folinic acid in patients with metastatic nasopharyngeal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Deoxycytidine; Feasibility Studies; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Nasopharyngeal Neoplasms; Paclitaxel; Prognosis; Quality of Life; Survival Rate | 2008 |
[A case of left urothelial carcinoma with multiple bone metastasis, liver metastasis and right adrenal metastasis successfully treated with combination chemotherapy of gemcitabine and carboplatin].
Topics: Adrenal Gland Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Tomography, X-Ray Computed; Urethral Neoplasms | 2008 |
[Effective gemcitabine plus S-1 treatment in elderly non-small cell lung cancer patients with multiple bone metastases].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Lung Neoplasms; Male; Oxonic Acid; Positron-Emission Tomography; Tegafur | 2009 |
Long-term disease stabilization during second-line gemcitabine in a refractory metastatic haemangioendothelioma.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Deoxycytidine; Doxorubicin; Gemcitabine; Hemangioendothelioma, Epithelioid; Humans; Ifosfamide; Liver Neoplasms; Lung Neoplasms; Male; Scapula; Time Factors; Treatment Outcome | 2009 |
Gemcitabine plus vinorelbine as an effective salvage chemotherapeutic regimen in cisplatin-refractory germ cell tumor.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Fatal Outcome; Gemcitabine; Humans; Male; Mediastinal Neoplasms; Neoplasms, Germ Cell and Embryonal; Salvage Therapy; Vinblastine; Vinorelbine; Young Adult | 2009 |
Bortezomib in combination with IGEV chemotherapy regimen for a primary refractory Hodgkin's lymphoma of bone.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Boronic Acids; Bortezomib; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Ifosfamide; Male; Positron-Emission Tomography; Prednisone; Pyrazines; Vinblastine; Vinorelbine | 2009 |
Anti-metastatic effects of liposomal gemcitabine in a human orthotopic LNCaP prostate cancer xenograft model.
Topics: Animals; Antimetabolites, Antineoplastic; Bone Neoplasms; Capillary Permeability; Cell Line, Tumor; Cells, Cultured; Deoxycytidine; Drug Evaluation, Preclinical; Gemcitabine; Humans; Liposomes; Luciferases; Male; Mice; Mice, Nude; Mice, SCID; Neoplasm Metastasis; Neoplasm Transplantation; Prostatic Neoplasms; Transduction, Genetic; Xenograft Model Antitumor Assays | 2009 |
Aerosol gemcitabine: preclinical safety and in vivo antitumor activity in osteosarcoma-bearing dogs.
Topics: Aerosols; Animals; Antimetabolites, Antineoplastic; Bone Neoplasms; Deoxycytidine; Dogs; Fas Ligand Protein; fas Receptor; Gemcitabine; Lung Neoplasms; Osteosarcoma | 2010 |
Enhanced anticancer effect of gemcitabine by genistein in osteosarcoma: the role of Akt and nuclear factor-kappaB.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Protocols; Apoptosis; Bone Neoplasms; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Synergism; Gemcitabine; Genistein; Humans; NF-kappa B; Osteosarcoma; Proto-Oncogene Proteins c-akt | 2010 |
Memoirs of differential radiation doses: Gemcitabine induced radiation recall.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carboplatin; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Gemcitabine; Humans; Mastectomy; Radiodermatitis; Radiotherapy; Radiotherapy Dosage | 2010 |
Biological activity of gemcitabine against canine osteosarcoma cell lines in vitro.
Topics: Animals; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Carboplatin; Cell Line, Tumor; Cell Survival; Deoxycytidine; Diphosphonates; Dog Diseases; Dogs; Dose-Response Relationship, Drug; Drug Therapy, Combination; Gemcitabine; Osteosarcoma; Pamidronate | 2010 |
Long-term administration of Wilms tumor-1 peptide vaccine in combination with gemcitabine causes severe local skin inflammation at injection sites.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; Cancer Vaccines; Cell Cycle Proteins; Chemotherapy, Adjuvant; Cholangiocarcinoma; Deoxycytidine; Dermatitis; Drug Administration Schedule; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Injections, Intradermal; Liver Neoplasms; Lymphocytes; Nuclear Proteins; Palliative Care; Radiotherapy, Adjuvant; RNA Splicing Factors; Skin | 2010 |
How fast can pancreatic cancer grow? A case of pancreatic carcinoma developed within 5 months after a negative examination to the advanced stage with multiple liver and bone metastases.
Topics: Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Liver Neoplasms; Male; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Pancreatic Neoplasms; Positron-Emission Tomography; Time Factors; Tomography, X-Ray Computed | 2011 |
Off-label use of oxaliplatin in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Off-Label Use; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Skin Neoplasms; Survival Rate; Treatment Outcome | 2011 |
A conjugate of gemcitabine with bisphosphonate (Gem/BP) shows potential as a targeted bone-specific therapeutic agent in an animal model of human breast cancer bone metastases.
Topics: Animals; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; Calcium; Creatinine; Deoxycytidine; Diphosphonates; Disease Models, Animal; Drug Delivery Systems; Female; Gemcitabine; Humans; Injections, Intralesional; Mice; Mice, Inbred BALB C; Mice, Nude; Positron-Emission Tomography; Technetium; Tumor Cells, Cultured | 2011 |
Gemcitabine with or without docetaxel and resection for recurrent osteosarcoma: the experience at Children's Memorial Hospital.
Topics: Adolescent; Antineoplastic Agents; Bone Neoplasms; Child; Combined Modality Therapy; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Neoplasm Recurrence, Local; Neurosurgical Procedures; Osteosarcoma; Retrospective Studies; Taxoids; Treatment Outcome | 2012 |
Genistein potentiates the anti-cancer effects of gemcitabine in human osteosarcoma via the downregulation of Akt and nuclear factor-κB pathway.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Drug Synergism; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Genistein; Humans; Mice; Mice, Inbred BALB C; NF-kappa B; Osteosarcoma; Proto-Oncogene Proteins c-akt; Signal Transduction | 2012 |
Efficacy and safety of gemcitabine-docetaxel combination therapy for recurrent or refractory high-grade osteosarcoma in China: a retrospective study of 18 patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; China; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Osteosarcoma; Retrospective Studies; Salvage Therapy; Taxoids; Treatment Outcome | 2012 |
Efficacy and toxicity of gemcitabine plus docetaxel combination as a second line therapy for patients with advanced stage soft tissue sarcoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Grading; Prognosis; Retrospective Studies; Salvage Therapy; Sarcoma; Survival Rate; Taxoids; Young Adult | 2012 |
Comparison of pirarubicin-based versus gemcitabine-docetaxel chemotherapy for relapsed and refractory osteosarcoma: a single institution experience.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Deoxycytidine; Disease-Free Survival; Docetaxel; Doxorubicin; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Ifosfamide; Kaplan-Meier Estimate; Male; Middle Aged; Osteosarcoma; Prospective Studies; Taxoids | 2013 |
Utility of inflammation-based prognostic scoring in patients given systemic chemotherapy first-line for advanced inoperable bladder cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; C-Reactive Protein; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Inflammation; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate; Urinary Bladder Neoplasms | 2012 |
Triplet platinum-based combination sequential chemotherapy improves survival outcome and quality of life of advanced non-small cell lung cancer patients.
Topics: Adenocarcinoma; Adolescent; Adrenal Gland Neoplasms; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Quality of Life; Survival Rate; Vinblastine; Vinorelbine; Young Adult | 2012 |
Impact of chemotherapy on hypercalcemia in breast and lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Calcium; Chi-Square Distribution; Cisplatin; Cyclophosphamide; Deoxycytidine; Diphosphonates; Docetaxel; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Hypercalcemia; Imidazoles; Linear Models; Logistic Models; Lung Neoplasms; Male; Middle Aged; Pamidronate; Parathyroid Hormone-Related Protein; Retrospective Studies; Severity of Illness Index; Statistics, Nonparametric; Taxoids; Young Adult; Zoledronic Acid | 2012 |
Toxic erythema of chemotherapy with periorbital and perioral involvement.
Topics: Antineoplastic Agents; Axilla; Bone Neoplasms; Child; Deoxycytidine; Docetaxel; Erythema; Female; Femur; Gemcitabine; Humans; Hyperpigmentation; Lung Neoplasms; Mouth; Orbit; Osteosarcoma; Taxoids; Treatment Outcome | 2012 |
Fatal cholestatic liver failure associated with gemcitabine therapy.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; Cholestasis, Intrahepatic; Deoxycytidine; Fatal Outcome; Female; Gemcitabine; Humans; Liver; Liver Failure, Acute; Liver Neoplasms; Middle Aged; Necrosis | 2003 |
Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Deoxycytidine; Docetaxel; Drug Administration Schedule; Drug Interactions; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Taxoids | 2004 |
Gemcitabine-associated scleroderma-like changes of the lower extremities.
Topics: Acetaminophen; Amitriptyline; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Neoplasms; Carcinoma, Transitional Cell; Cisplatin; Clonazepam; Deoxycytidine; Dermis; Doxorubicin; Edema; Gemcitabine; Humans; Infusions, Intravenous; Leg; Lung Neoplasms; Male; Methotrexate; Middle Aged; Morphine; Scleroderma, Diffuse; Vinblastine | 2004 |
[Short-term efficacy of combined chemotherapy of gemcitabine and cisplatin on advanced hormone refractory prostate cancer].
Topics: Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Castration; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Prostatic Neoplasms; Ribonucleotide Reductases; Survival Rate | 2004 |
[A case of recurrence and systemic metastasis of oral cancer successfully treated with combination chemotherapy of cisplatin and gemcitabine].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Mouth Neoplasms; Neoplasm Recurrence, Local; Salvage Therapy | 2005 |
Aerosol gemcitabine inhibits the growth of primary osteosarcoma and osteosarcoma lung metastases.
Topics: Aerosols; Animals; Antimetabolites, Antineoplastic; Bone Neoplasms; Deoxycytidine; Disease Models, Animal; fas Receptor; Gemcitabine; Lung Neoplasms; Mice; Mice, Nude; Osteosarcoma; Tumor Cells, Cultured | 2005 |
Gemcitabine inhibits viability, growth, and metastasis of osteosarcoma cell lines.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Bone Neoplasms; Cell Division; Cell Line, Tumor; Cell Survival; Deoxycytidine; DNA; Fibroblasts; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Inbred C3H; Neoplasm Transplantation; Osteosarcoma | 2005 |
Gemcitabine radiosensitization after high-dose samarium for osteoblastic osteosarcoma.
Topics: Adolescent; Adult; Alkaline Phosphatase; Analgesics, Non-Narcotic; Antigens, CD34; Bone and Bones; Bone Neoplasms; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Image Processing, Computer-Assisted; Neoplasm Metastasis; Organometallic Compounds; Organophosphorus Compounds; Osteosarcoma; Pain; Positron-Emission Tomography; Radiation-Sensitizing Agents; Radiopharmaceuticals; Remission Induction; Samarium; Sarcoma; Stem Cells; Time Factors | 2005 |
Zoledronic acid (Zometa) enhances the cytotoxic effect of gemcitabine and fluvastatin: in vitro isobologram studies with conventional and nonconventional cytotoxic agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cytoplasm; Deoxycytidine; Diphosphonates; DNA Fragmentation; Drug Antagonism; Drug Synergism; Epirubicin; Fatty Acids, Monounsaturated; Female; Fluvastatin; Gemcitabine; Humans; Imidazoles; Indoles; Lung Neoplasms; Male; Prostatic Neoplasms; Zoledronic Acid | 2006 |
A 99mTc-labeled gemcitabine bisphosphonate drug conjugate as a probe to assess the potential for targeted chemotherapy of metastatic bone cancer.
Topics: Animals; Bone Neoplasms; Deoxycytidine; Diphosphonates; Female; Gemcitabine; Kidney; Liver; Mice; Mice, Inbred BALB C; Technetium; Tissue Distribution | 2006 |
[Second-line chemotherapy with gemcitabine and cisplatin for urothelial cancer previously treated with or resistant to M-VAC therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Methotrexate; Middle Aged; Prognosis; Remission Induction; Urologic Neoplasms; Vinblastine | 2006 |
[A case of intrahepatic cholangiocarcinoma effectively treated by hepatic arterial infusion chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Bone Neoplasms; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Hepatic Artery; Humans; Infusion Pumps, Implantable; Infusions, Intra-Arterial; Leucovorin; Lymph Nodes; Lymphatic Metastasis; Middle Aged | 2006 |
A case of Guillain-Barré syndrome in a patient with non small cell lung cancer treated with chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Guillain-Barre Syndrome; Humans; Immunoglobulins, Intravenous; Lung Neoplasms; Middle Aged | 2006 |
Corruption of the Fas pathway delays the pulmonary clearance of murine osteosarcoma cells, enhances their metastatic potential, and reduces the effect of aerosol gemcitabine.
Topics: Aerosols; Animals; Apoptosis; Blotting, Western; Bone Neoplasms; Deoxycytidine; fas Receptor; Flow Cytometry; Gemcitabine; Lung Neoplasms; Mice; Mice, Inbred BALB C; Osteosarcoma; RNA, Messenger; Survival Rate; Tumor Cells, Cultured; Up-Regulation | 2007 |
188Re-labelled gemcitabine/bisphosphonate (Gem/BP): a multi-functional, bone-specific agent as a potential treatment for bone metastases.
Topics: Animals; Bone and Bones; Bone Neoplasms; Cattle; Combined Modality Therapy; Deoxycytidine; Diphosphonates; Durapatite; Etidronic Acid; Female; Gemcitabine; Humans; In Vitro Techniques; Mice; Mice, Inbred BALB C; Organometallic Compounds; Radioisotopes; Radiopharmaceuticals; Rhenium; Tissue Distribution | 2008 |
Measurement of plasma concentration of gemcitabine and its metabolite dFdU in hemodialysis patients with advanced urothelial cancer.
Topics: Antimetabolites, Antineoplastic; Area Under Curve; Bone Neoplasms; Cystectomy; Deoxycytidine; Fatal Outcome; Floxuridine; Gemcitabine; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Renal Dialysis; Renal Insufficiency; Ureteral Neoplasms; Urinary Bladder Neoplasms | 2008 |
Tumor resensitization to erlotinib following brief substitution of cetuximab.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers, Tumor; Bone Neoplasms; Cetuximab; Deoxycytidine; Drug Eruptions; Drug Interactions; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Proteins; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2008 |
Cotton-wool spots associated with pancreatic carcinoma.
Topics: Adrenal Gland Neoplasms; Biomarkers, Tumor; Bone Neoplasms; Deoxycytidine; Eye Neoplasms; Fatal Outcome; Female; Gemcitabine; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Pancreatic Neoplasms; Vision Disorders | 2001 |
[An autopsy case of pulmonary and central nervous system metastatic osteosarcoma treated with thirty-six courses of chemotherapy over four years].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carboplatin; Cisplatin; Dacarbazine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Methotrexate; Osteosarcoma; Paclitaxel; Spinal Cord Neoplasms; Survivors; Taxoids; Vincristine; Vindesine | 2002 |